Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces
CompanyDrug

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

Beijing Northland Biotechnology Co., Ltd. announced that its independently developed Class 1 innovative gene therapy, Sedominji Injection (brand name: Huasuoling®), completed its first nationwide shipment at the production base of…

GeneScience's GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody
CompanyDrug

GeneScience’s GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

Youcare Pharmaceutical's YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program
CompanyDrug

Youcare Pharmaceutical’s YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
CompanyDrug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

- Advertisement -
Ad image
AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

CompanyDeals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

CompanyDeals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

CompanyDrug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

CompanyDrug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

CompanyDrug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

CompanyDrug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

CompanyDrug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline
Company

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

CompanyDeals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Show More